Antimitochondrial agents: A new class of anticancer agents;Contribution de la Société francophone de recherche en pédiatrie (SFRP). « Les agents antimitochondriaux: Une nouvelle classe d'agents anticancéreux »

Archives de Pediatrie

Volumn 13, Issue 1, 2006, Pages 69-75

  Andre N ^a   Rome, A ^a   Carre M ^b  

^a TIMONE HOSPITAL   (France)

^b CNRS   (France)

Author keywords

Apoptosis; Chemotherapy; Mitochondria; Neoplasms

Indexed keywords

4' CHLORODIAZEPAM; 6 [3 (1 ADAMANTYL) 4 HYDROXYPHENYL] 2 NAPHTHOIC ACID; ANTIMITOCHONDRIAL AGENT; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; BETULIC ACID; CASPASE; DEOXYADENOSINE; ETOPOSIDE; FENRETINIDE; LONIDAMINE; MEROCYANINE; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; NAVELBINE; PACLITAXEL; PROTEIN BCL 2; UNCLASSIFIED DRUG; VINBLASTINE;

APOPTOSIS; CANCER GROWTH; CHEMOTHERAPY; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; LEUKEMIA; MITOCHONDRION; PATHOGENESIS; REVIEW;

EID: 30144436636     PISSN: 0929693X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcped.2005.10.003     Document Type: Article

References (48)

1. N. Andre Hippocrates of Cos and apoptosis Lancet 361 2003 1306
2. J.F. Kerr, A.H. Wyllie, and A.R. Currie Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics Br. J. Cancer 26 1972 239 257
3. G. Melino, R.A. Knight, and D.R. Green Publications in cell death: the golden age Cell Death Differ. 8 2001 1 3
4. M.B. Graeber, and L.B. Moran Mechanisms of cell death in neurodegenerative diseases: fashion, fiction, and facts Brain Pathol. 12 2002 385 390
5. C.G. Ferreira, M. Epping, F.A. Kruyt, and G. Giaccone Apoptosis: target of cancer therapy Clin. Cancer Res. 8 2002 2024 2034
6. U. Fischer, and K. Schulze-Osthoff New approaches and therapeutics targeting apoptosis in disease Pharmacol. Rev. 57 2005 187 215
7. P. Costantini, E. Jacotot, D. Decaudin, and G. Kroemer Mitochondrion as a novel target of anticancer chemotherapy J. Natl. Cancer Inst. 92 2000 1042 1053
8. J.M. Grad, E. Cepero, and L.H. Boise Mitochondria as targets for established and novel anti-cancer agents Drug Resist. Updat. 4 2001 85 91
9. K.M. Debatin, D. Poncet, and G. Kroemer Chemotherapy: targeting the mitochondrial cell death pathway Oncogene 21 2002 8786 8803
10. A.S. Don, and P.J. Hogg Mitochondria as cancer drug targets Trends Mol. Med. 10 2004 372 378
11. T. Morisaki, and M. Katano Mitochondria-targeting therapeutic strategies for overcoming chemoresistance and progression of cancer Curr. Med. Chem. 10 2003 2517 2521
12. V. Weissig, S.V. Boddapati, G.M. D'Souza, and S.M. Cheng Targeting of Low-Molecular Weight Drugs to Mammalian Mitochondria Drug Design Rev. 1 2004 15 28
13. B.B. Wolf, and D.R. Green Suicidal tendencies: apoptotic cell death by caspase family proteinases J. Biol. Chem. 274 1999 20049 20052
14. M.G. Grütter Caspases: key players in programmed cell death Cur. Opin. Struct. Biol. 10 2000 649 655
15. J.C. Reed Bcl-2 family proteins Oncogene 17 1998 3225 3236
16. S. Cory, and J.M. Adams The Bcl2 family: regulators of the cellular life-or-death switch Nat. Rev. Cancer 2 2002 647 656
17. D.D. Newmeyer, D.M. Farschon, and J.C. Reed Cell-free apoptosis in Xenopus egg extracts: inhibition by Bcl-2 and requirement for an organelle fraction enriched in mitochondria Cell 79 1994 353 364
18. N. Zamzami, P. Marchetti, M. Castedo, C. Zanim, J.L. Vayssiere, and P.X. Petit Reduction in mitochondrial potential constitutes an early irreversible step of programmed lymphocyte death in vivo J. Exp. Med. 181 1995 1661 1672
19. D.R. Green, and G. Kroemer The pathophysiology of mitochondrial cell death Science 305 2004 626 629
20. P. Vandenabeele, X. Saelens, N. Festjens, L. Vande Walle, M. van Gurp, and G. van Loo Toxic proteins released from mitochondria in cell death Oncogene 23 2004 2861 2874
21. H. Pelicano, D. Carney, and P. Huang ROS stress in cancer cells and therapeutic implications Drug Resist. Updat. 7 2004 97 110
22. P.S. Brookes, Y. Yoon, J.L. Robotham, M.W. Anders, and S.S. Sheu Calcium, ATP, and ROS: a mitochondrial love-hate triangle Am. J. Physiol. Cell Physiol. 287 2004 C817 C833
23. J.B. Custodio, C.M. Cardoso, V.M. Madeira, and L.M. Almeida Mitochondrial permeability transition induced by the anticancer drug etoposide Toxicol. In Vitro 15 2001 265 270
24. N. Andŕ, D. Braguer, G. Brasseur, A. Goncalves, D. Lemesle-Meunier, and S. Guise Paclitaxel induces release of cytochrome c from mitochondria isolated from human neuroblastoma cells' Cancer Res. 60 2000 5349 5353
25. N. Andŕ, M. Carre, G. Brasseur, B. Pourroy, H Kovacic, and C. Briand Paclitaxel targets mitochondria upstream of caspase activation in intact human neuroblastoma cells FEBS Lett. 532 2002 256 260
26. M. Carŕ, G. Carles, N. Andŕ, S. Douillard, J. Ciccolini, and C. Briand Involvement of microtubules and mitochondria in the antagonism of arsenic trioxide on paclitaxel-induced apoptosis Biochem. Pharmacol. 63 2002 1831 1842
27. L. Ravagnan, I. Marzo, P. Costantini, S.A. Susin, N. Zamzami, and P.X. Petit Lonidamine triggers apoptosis via a direct, Bcl-2-inhibited effect on the mitochondrial permeability transition pore Oncogene 18 1999 2537 2546
28. S. Fulda, C. Scaffidi, S.A. Susin, P.H. Krammer, G. Kroemer, and M.E. Peter Activation of mitochondria and release of mitochondrial apoptogenic factors by betulinic acid J. Biol. Chem. 273 1998 33942 33948
29. M. Watabe, K. Machida, and H. Osada MT-21 is a synthetic apoptosis inducer that directly induces cytochrome c release from mitochondria Cancer Res. 60 2000 5214 5222
30. A. Chadderton, D.J. Villeneuve, and S. Gluck Role of specific apoptotic pathways in the restoration of paclitaxel- induced apoptosis by valspodar in doxorubicin-resistant MCF-7 breast cancer cells Breast Cancer Res. Treat. 59 2000 231 244
31. T. Teitz, J.M. Lahti, and V.J. Kidd Aggressive childhood neuroblastomas do not express caspase-8:: an important component of programmed cell death J. Mol. Med. 79 2001 428 436
32. I. Petak, L. Douglas, and D.M. Tillman Pediatric rhabdomyosarcoma cell lines are resistant to Fas-induced apoptosis and highly sensitive to TRAIL-induced apoptosis Clin. Cancer Res. 6 2000 4119 4127
33. J.P. Howard, J.M. Maris, L.S. Kersun, J.P. Huberty, S.C. Cheng, and R.A. Hawkins Tumor response and toxicity with multiple infusions of high dose 131I-MIBG for refractory neuroblastoma Pediatr. Blood Cancer 44 2005 232 239
34. T. Hirsch, D. Decaudin, S.A. Susin, P. Marchetti, N. Larochette, and M. Resche-Rigon PK11195, a ligand of the mitochondrial benzodiazepine receptor, facilitates the induction of apoptosis and reverses Bcl-2-mediated cytoprotection Exp. Cell Res. 241 1998 426 434
35. D. Decaudin Peripheral benzodiazepine receptor and its clinical targeting Anticancer Drugs 15 2004 737 745
36. L.D. Piro Apoptosis, Bcl-2 antisense, and cancer therapy Oncology (Huntingt.) 18 Suppl 10 2004 5 10
37. S. Fulda, and K.M. Debatin Sensitization for anticancer drug-induced apoptosis by betulinic acid Neoplasia 7 2005 162 170
38. L. Miccoli, F. Poirson-Bichat, F. Sureau, R. Bras Goncalves, Y. Bourgeois, and B. Dutrillaux Potentiation of lonidamine and diazepam, two agents acting on mitochondria, in human glioblastoma treatment J. Natl. Cancer Inst. 90 1998 1400 1406
39. L. Orlandi, N. Zaffaroni, A. Bearzatto, R. Villa, C. De Marco, and R. Silvestrini Lonidamine as a modulator of taxol activity in human ovarian cancer cells: effects on cell cycle and induction of apoptosis Int. J. Cancer 78 1998 377 384
40. I. Jeremias, H.H. Steiner, A. Benner, K.M. Debatin, and C. Herold-Mende Cell death induction by betulinic acid, ceramide and TRAIL in primary glioblastoma multiforme cells Acta Neurochir. (Wien) 146 2004 721 729
41. S. Fulda, I. Jeremias, H.H. Steiner, T. Pietsch, and K.M. Debatin Betulinic acid: a new cytotoxic agent against malignant brain-tumor cells Int. J. Cancer 82 1999 435 441
42. H. Ehrhardt, S. Fulda, M. Fuhrer, K.M. Debatin, and I. Jeremias Betulinic acid-induced apoptosis in leukemia cells Leukemia 18 2004 1406 1412
43. J.L. Slack, S. Waxman, G. Tricot, M.S. Tallman, and C.D. Bloomfield Advances in the management of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide Oncologist 7 Suppl 1 2002 1 13
44. S.Y. Huan, C.H. Yang, and Y.C. Chen Arsenic trioxide therapy for relapsed acute promyelocytic leukaemia: an useful salvage therapy Leuk. Lymphoma 38 2000 283 293
45. E. Pasquier, M. Carre, B. Pourroy, L. Camoin, O. Rebai, and C. Briand Antiangiogenic activity of paclitaxel is associated with its cytostatic effect, mediated by the initiation but not completion of a mitochondrial apoptotic signaling pathway Mol. Cancer Ther. 3 2004 1301 1310
46. H.J. Kwon, J.S. Shim, J.H. Kim, H.Y. Cho, Y.N. Yum, and S.H. Kim Betulinic acid inhibits growth factor-induced in vitro angiogenesis via the modulation of mitochondrial function in endothelial cells Jpn. J. Cancer Res. 93 2002 417 425
47. J. Hu, J. Fang, Y. Dong, S.J. Chen, and Z. Chen Arsenic in cancer therapy Anticancer Drugs 16 2005 119 127
48. I.N. Shokolenko, M.F. Alexeyev, F.M. Robertson, S.P. LeDoux, and G.L. Wilson The expression of Exonuclease III from E.:coli in mitochondria of breast cancer cells diminishes mitochondrial DNA repair capacity and cell survival after oxidative stress DNA Repair (Amst.) 2 2003 471 482